
    
      This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the
      efficacy and safety of pridopidine 45 mg BID in patients with early stage HD.

      Eligible patients who completed the Main Study (65 to 78 weeks) will have the option to
      enroll into an open-label extension.
    
  